This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

GSK626616

GlaxoSmithKline plc

Drug Names(s): 626616

Description: GSK626616 is a Dual Specificity Tyrosine Phosphorylation Regulated Kinase-3 (DYRK3) antagonist.

Deal Structure: This drug was discovered by GSK based on Human Genome Sciences technology. Human Genome Sciences is entitled to receive a milestone payment if the compound moves through clinical development into registration. Human Genome Scienes is also entitled to worldwide royalties of up to 10% if this compound is commercialized, and also has a 20% co-promotion option in North America and Europe.

In July 2012, GlaxoSmithKline and Human Genome Sciences entered into a definitive agreement under which GSK will acquire HGS for US$14.25 per share in cash. The acquisition was completed in August 2012.


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug